Document is current

Article History

First Online: 17 June 2016

Competing interests

: At the time the manuscript was prepared and submitted, A.B. was an employee and shareholder of AbbVie, D.Do. was an employee and shareholder of Lundbeck, and P.M. was an employee and shareholder of Pierre Fabre. T.S. is an employee and shareholder of Janssen. D.De. is an employee and shareholder of Alkermes. J.B. is an employee and shareholder of Lundbeck. J.W. is an employee and shareholder of Eli Lilly. M.M is an employee of the Institut de Recherche Servier. E.P. and T.B. are employees and shareholders of Roche. B.A. and P.O'D. are employees and shareholders of Pfizer. U.E. is an employee of Boehringer-Ingelheim. In the past three years, M.G. has received consulting compensation from Abbott, Dart, Lundbeck, Neurocrine, Omeros, Otsuka, and Sunovion, and he holds an equity interest in San Diego Instruments. He also has research grant support from the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the US Veteran's Administration (VISN 22 Mental Illness Research, Education, and Clinical Center. M.M., E.K. and P.S. have no competing interests.